These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33866591)

  • 21. Evaluation of Fixed-Dose Four-Factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal in Patients with Intracranial Hemorrhage.
    Scott R; Kersten B; Basior J; Nadler M
    J Emerg Med; 2018 Jun; 54(6):861-866. PubMed ID: 29510892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inactivated Four-Factor Prothrombin Complex Concentrate Dosing Practices for Reversal of Warfarin-Related Intracranial Hemorrhage.
    Rhoney DH; La M; Merz M; Cook A; Owusu KA; Roels C; Blunck J; Shewmaker J; Sangha KS; Farrokh S; Lewin J; Chester KW; Human T; Bledsoe K; Greene K; Levesque M; Rocker JC; Davis G; Neyens R; Lassiter TF; Adriance SM
    Neurocrit Care; 2021 Aug; 35(1):130-138. PubMed ID: 33219462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-dose Prothrombin Complex Concentrate for Warfarin-Associated Intracranial Hemorrhage with INR Less Than 2.0.
    Zemrak WR; Smith KE; Rolfe SS; May T; Trowbridge RL; Hayes TL; Grindlinger GA; Seder DB
    Neurocrit Care; 2017 Dec; 27(3):334-340. PubMed ID: 28660341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reversal of factor Xa inhibitors associated intracranial haemorrhage at a tertiary medical centre.
    Milioglou L; Liao K; Traeger J; McKenzie C; Burrelli C; Khunayfir AKB; Makii J; Hoffer A
    Blood Coagul Fibrinolysis; 2022 Jul; 33(5):261-265. PubMed ID: 35153278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of prothrombin complex concentrate in the management of oral factor Xa inhibitors associated major bleed assessed by ISTH and ANNEXA-4 criteria.
    Dev P; Abousaab C; Zhou C; Sarode R
    J Thromb Thrombolysis; 2022 Feb; 53(2):249-256. PubMed ID: 34373984
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and Effectiveness of Factor VIII Inhibitor Bypassing Activity (FEIBA) and Fresh Frozen Plasma in Oral Anticoagulant-Associated Intracranial Hemorrhage: A Retrospective Analysis.
    Yin EB; Tan B; Nguyen T; Salazar M; Putney K; Gupta P; Suarez JI; Bershad EM
    Neurocrit Care; 2017 Aug; 27(1):51-59. PubMed ID: 28243997
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world management of oral factor Xa inhibitor-related bleeds with reversal or replacement agents including andexanet alfa and four-factor prothrombin complex concentrate: a multicenter study.
    Coleman CI; Dobesh PP; Danese S; Ulloa J; Lovelace B
    Future Cardiol; 2021 Jan; 17(1):127-135. PubMed ID: 32618210
    [No Abstract]   [Full Text] [Related]  

  • 28. 3-Factor Versus 4-Factor Prothrombin Complex Concentrate for Warfarin Reversal in Severe Bleeding: A Multicenter, Retrospective, Propensity-Matched Pilot Study.
    Jones GM; Erdman MJ; Smetana KS; Mohrien KM; Vandigo JE; Elijovich L
    J Thromb Thrombolysis; 2016 Jul; 42(1):19-26. PubMed ID: 26721625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modified version of the American College of Cardiology's recommendation for low-dose prothrombin complex concentrate is effective for warfarin reversal.
    Gilbert BW; Morton L; Huffman JB; Roemer K; Potter A; Cassidy CD; Vasquez DG
    Am J Emerg Med; 2020 Apr; 38(4):806-809. PubMed ID: 31864879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A French multicenter randomised trial comparing two dose-regimens of prothrombin complex concentrates in urgent anticoagulation reversal.
    Kerebel D; Joly LM; Honnart D; Schmidt J; Galanaud D; Negrier C; Kursten F; Coriat P;
    Crit Care; 2013 Jan; 17(1):R4. PubMed ID: 23305460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of 3 Different Prothrombin Complex Concentrate Regimens for Emergent Warfarin Reversal: PCCWaR Study.
    Dietrich SK; Rowe S; Cocchio CA; Harmon AJ; Nerenberg SF; Blankenship PS
    Ann Pharmacother; 2021 Aug; 55(8):980-987. PubMed ID: 33305592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emergent reversal of oral factor Xa inhibitors with four-factor prothrombin complex concentrate.
    Lipari L; Yang S; Milligan B; Blunck J
    Am J Emerg Med; 2020 Dec; 38(12):2641-2645. PubMed ID: 33041150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome of intracranial bleeding managed with prothrombin complex concentrate in patients on direct factor Xa inhibitors or vitamin K antagonists.
    Bavalia R; Abdoellakhan R; Beenen LF; Brekelmans MPA; Olie RH; Ten Cate H; Huisman MV; Kruip M; Middeldorp S; Meijer K; Hutten BA; Coppens M
    Thromb Res; 2020 Dec; 196():404-409. PubMed ID: 33011638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of andexanet alfa versus four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-related intracranial hemorrhage in the US.
    Fanikos J; Goldstein JN; Lovelace B; Beaubrun AC; Blissett RS; Aragão F
    J Med Econ; 2022; 25(1):309-320. PubMed ID: 35168455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage.
    Giovino A; Shomo E; Busey KV; Case D; Brockhurst A; Concha M
    Clin Neurol Neurosurg; 2020 Aug; 195():106070. PubMed ID: 32679541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Four-factor prothrombin complex concentrate administration after expanding intracranial hemorrhage status post administration of andexanet alfa.
    Blackburn M
    Am J Emerg Med; 2022 Dec; 62():144.e1-144.e3. PubMed ID: 36038405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fixed Versus Variable Dosing of Prothrombin Complex Concentrate in Vitamin K Antagonist-Related Intracranial Hemorrhage: A Retrospective Analysis.
    Abdoellakhan RA; Miah IP; Khorsand N; Meijer K; Jellema K
    Neurocrit Care; 2017 Feb; 26(1):64-69. PubMed ID: 27052728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Andexanet alfa versus PCC products for factor Xa inhibitor bleeding: A systematic review with meta-analysis.
    White CM; Caroti KS; Bessada Y; Hernandez AV; Baker WL; Dobesh PP; van Haalen H; Rhodes K; Coleman CI
    Pharmacotherapy; 2024 May; 44(5):394-408. PubMed ID: 38721837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversal of Apixaban and Rivaroxaban Using Activated Prothrombin Complex Concentrates in Patients with Major Bleeding.
    Sheikh-Taha M; Crawley RM
    Am J Cardiovasc Drugs; 2020 Jun; 20(3):295-299. PubMed ID: 31709499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modeling the Clinical Implications of Andexanet Alfa in Factor Xa Inhibitor-Associated Intracerebral Hemorrhage.
    Chuck CC; Kim D; Kalagara R; Rex N; Madsen TE; Mahmoud L; Thompson BB; Jones RN; Furie KL; Reznik ME
    Neurology; 2021 Nov; 97(21):e2054-e2064. PubMed ID: 34556569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.